MediPharm Labs Stock (TSX: LABS) (OTCQX: MEDIF) - Investor Dashboard

Summary

Financials (09/30/19)

Capital Structure (11/12/19)

Company Brief

As Canada’s leader in purified cannabis concentrates, MediPharm Labs (TSX: LABS) (OTCQX: MEDIF), has the distinction of being the first company in Canada to become a licensed producer exclusively for cannabis oil production under the (ACMPR) without first receiving a cannabis cultivation license.  Founded in Canada in 2015 with the mission to manufacture products extracted from cannabis to the highest-quality standard for global distribution.

MediPharm received its Health Canada license for cannabis oil production in March 2018 and has been operational since June 2018. The company has an annual dried cannabis processing capacity of 300,000 kilograms.

The company has a singular focus which is its defining competitive advantage. The company believes that whether for medical or adult-use products, precisely dosed, consumer-safe purified cannabis concentrates will be a base ingredient in high demand for all advanced derivative products.

Featured Video

Highlights

• First Canadian LP to get oil production license without cultivation license
• B2B service provider to other LPs, with eight long-term private and white label agreements and various spot agreements
• Processing capacity of 300,000 kilograms with the ability to expand to 500,000-kilogram capacity
• Runs five supercritical CO2 extraction lines
• Pursuing license in Australia, with facility under construction
• Management team with deep experience in global bio-pharma, healthcare, energy and biotech manufacturing

Growth Strategy

• Maintain singular focus on extraction
• Add additional clients for contract processing or white label production
• Expand internationally beyond Canada and Australia
• Develop intellectual property, with focus on downstream proprietary fractionation, isolation and chromatography
• Funded phase two expansion plans slated for completion in Q2 2019
• Wholesale purchase agreements with Newstrike Brands and Cronos Group
• Strategic supply agreement with Canopy Growth; cannabis concentrate agreements with The Supreme Cannabis Company and TerrAscend

Differentiators

• Focused on producing cannabis oils and extracts
• Laboratory and manufacturing rooms have been constructed to cGMP standards with ISO rated clean rooms
• Constructing a facility in Australia anticipated to be operational in spring 2019; Australian extraction lab to serve as an import-export hub to other markets within the Asia-Pacific region
• Research-driven, with partnerships with accredited teaching hospitals and universities and a research license from Health Canada
• Approved supplier to the Ontario Cannabis Store

David M. Kideckel
Alta Corp Capital

Devin Schilling
PI Financial

Kimberly Hedlin
Canaccord Genuity

Scott Fortune
ROTH Capital Partners

Martin Landry
GMP Securities

Ben Isaacson
Scotia Capital

Greg McLeish
Mackie Research